Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Mantle Cell Lymphoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Mantle Cell Lymphoma

ASH 2019: KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.
Read More >>

ASH 2019: Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies

FDA Approves Zanubrutinib for Relapsed/Refractory MCL

Cirmtuzumab/Ibrutinib Study Expands to Include Patients With MCL

Expert Shares Insight on Precision Medicine Efforts in MCL

View More Stories >>

View Conference Coverage

2019 San Antonio Breast Cancer Symposium

2019 ASH Annual Meeting

2019 International Congress of the Society for Melanoma Research

2019 State of the Science Summit on Genitourinary Cancers in Nashville

2019 State of the Science Summit on Hematologic Malignancies in Chicago

Dr. Rule on Potential for CAR T-Cell Therapy in MCL

$Dr. Gerson on Updates in Relapsed/Refractory MCL$

Dr. Gerson on Updates in Relapsed/Refractory MCL

Dr. Goy on Treating Older Patients With MCL

Dr. Rule on the FDA Approval of Zanubrutinib in MCL

Dr. Rule on the Future Treatment Paradigm in MCL

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Practical Advice on the Future Management of MCL

R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

$Selection of a BTK Inhibitor in Relapsed/Refractory MCL$

Selection of a BTK Inhibitor in Relapsed/Refractory MCL

Mantle Cell Lymphoma: An Overview on Frontline Therapy

Highlights from ASH 2017: Mantle Cell Lymphoma

Investigational Treatment in Mantle Cell Lymphoma

Future Therapy: Bruton's TKI Containing Combinations in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

First-Generation BTK Inhibition in Mantle Cell Lymphoma

Advice for Future Management of Mantle Cell Lymphoma

Non-BTKi Agents' Role in Mantle Cell Lymphoma

MCL: Novel BTK Inhibitor Combination Strategies

$Identifying Unmet Needs in Relapsed/Refractory MCL$

Differentiating BTK Inhibitor Mechanisms of Action in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Ibrutinib in Relapsed Mantle Cell Lymphoma

Drs Danilov, Goy, Leonard, Pagel, and Schuster, discuss ibrutinib (Imbruvica) as a treatment in relapsed mantle cell lymphoma. View Now

Treatments for Relapsed Mantle Cell Lymphoma

Brad S. Kahl, MD, and Richard R. Furman, MD, explain available treatment options for relapsed mantle cell lymphoma. View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

OncLive News Network On Location: ASH 2019 Day 2